文献速递细菌感染、耐药与抗菌药物医院感染防控

如何调整肠道微生物群移植方案以降低侵袭性多重耐药菌感染风险

How to adapt an intestinal microbiota transplantation programme to reduce the risk of invasive multidrug-resistant infection.
PubMed 文献 · Clin Microbiol Infect · 2021-11-23

本文为专家指南与同行评议临床研究的综述,阐述如何为多重耐药菌(MDRO)定植且具侵袭性感染风险的患者建立肠道微生物群移植(IMT)临床路径。内容涵盖供者筛查(包括MDRO与SARS-CoV-2)、受者免疫状态考量、移植时机(无活动性感染时,若未来需免疫抑制则至少提前2周)、随访不良事件及以预防侵袭性疾病为主要成功指标而非肠道去定植。

要点

  • IMT适用于直肠或粪便筛查检出MDRO且因免疫状态改变有侵袭性感染风险者,或复发性MDRO侵袭性疾病再发风险者。
  • 供者筛查应包括有理论或已证实传播风险的病原体(含MDRO本身和SARS-CoV-2),并考虑受者免疫抑制状态。
  • IMT应在患者无活动性感染时进行,无需额外抗生素;若未来需免疫抑制,至少提前2周以保障定植。

核心结论

  • 预防侵袭性疾病是IMT的主要成功指标,而非以肠道去定植作为二分类结局。

研究设计与样本

  • 本综述纳入并讨论专家指南与同行评议的临床研究。

主要发现

  • IMT提供给直肠或粪便筛查检出MDRO且因免疫状态改变有侵袭性感染风险的患者,或复发性MDRO侵袭性疾病再发风险者。
  • 供者筛查包括有理论或已证实传播风险的病原体(含MDRO本身和SARS-CoV-2),并考虑潜在受者的相对免疫抑制状态。
  • IMT在患者无活动性感染时进行,无需额外抗生素;若未来需免疫抑制,至少提前2周实施以确保有足够时间定植。
  • 随访关注IMT不良效应;如需抗生素,临床医生应与IMT多学科团队讨论其对肠道微生物组的影响。
  • 重复IMT需逐例考虑。

关键数值与推荐

  • 若未来需免疫抑制,IMT至少提前2周实施。

临床怎么用

  • 为MDRO定植且具侵袭性感染风险的患者建立临床IMT路径,供者筛查涵盖MDRO与SARS-CoV-2并考虑受者免疫状态。
  • IMT安排在无活动性感染时,无需额外抗生素;若未来需免疫抑制则至少提前2周。
  • 随访IMT不良效应;需用抗生素时与IMT多学科团队讨论对肠道微生物组的影响。
  • 以预防侵袭性疾病为主要成功指标,不以肠道去定植作为二分类结局。
  • 重复IMT逐例考虑。

局限性

  • 未来研究领域应包括考虑临床结局与成本效益的随机研究,以及更好地理解机制以识别治疗成功的标志物和可用于治疗的功能性微生物组组分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vulnerable patients with intestinal colonization of multidrug-resistant organisms (MDROs) are recognized to be at increased risk of invasive MDRO-driven infection. Intestinal microbiota transplantation (IMT, also called faecal microbiota transplant) is the transfer of healthy screened donor stool to an affected recipient, and recent interest has focused on its impact on the reduction of invasive MDRO infection. OBJECTIVES: To describe how to establish a clinical IMT pathway for patients at risk of MDRO invasive infection, with special considerations for optimizing administration and assessment of endpoints. SOURCES: Expert guidelines and peer-reviewed clinical studies are encompassed and discussed. CONTENT: IMT is offered to patients with MDROs detected on rectal or stool screening and either at risk of MDRO invasive infection due to altered immune status or those with recurrent MDRO-mediated invasive disease and considered at risk of further disease. Donor screening should include pathogens with theoretical or demonstrated risk of transmission (including MDROs themselves and SARS-CoV-2) and take into consideration the relative immunosuppressed state of potential recipients. Delivery of IMT is timed for when the patient is free from active infection, but no additional antibiotics are indicated. If administered when future immunosuppression is to take place, IMT is aligned at least 2 weeks beforehand to ensure sufficient time for engraftment. Patients are followed up in terms of adverse effects from IMT and clinicians are advised to discuss with the IMT multidisciplinary team on choice of antibiotics if needed to take into consideration the impact upon the intestinal microbiome. Prevention of invasive disease is the primary measure of success, rather than using intestinal decolonization as a binary outcome. Repeat IMT is considered case by case. IMPLICATIONS: Future research areas should include randomized studies that consider clinical outcomes and cost-effectiveness, and better understanding of mechanisms to identify markers of treatment success and functional microbiome components that could be used therapeutically.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Ghani R, Mullish BH, Davies FJ, et al. How to adapt an intestinal microbiota transplantation programme to reduce the risk of invasive multidrug-resistant infection. Clin Microbiol Infect. 2021. PMID: 34826617. doi:10.1016/j.cmi.2021.11.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。